Biodexa Pharmaceuticals Plc, a company in the pharmaceutical sector, has filed a Registration Statement on Form F-1 with the United States Securities and Exchange Commission (SEC) on March 18, 2024. The SEC, through a letter addressed to Stephen Stamp, the Chief Executive Officer of Biodexa Pharmaceuticals, dated March 20, 2024, has informed the company that it has not reviewed and will not review the registration statement. The SEC's letter also reminds the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The letter further refers Biodexa Pharmaceuticals to Rules 460 and 461 should they wish to request acceleration of the process. Chris Edwards from the SEC's Division of Corporation Finance Office of Life Sciences has been designated as the contact person for any questions Biodexa Pharmaceuticals might have.

Biodexa Pharmaceuticals Plc, a company in the pharmaceutical sector, has filed a Registration Statement on Form F-1 with the United States Securities and Exchange Commission (SEC) on March 18, 2024. The SEC, through a letter addressed to Stephen Stamp, the Chief Executive Officer of Biodexa Pharmaceuticals, dated March 20, 2024, has informed the company that it has not reviewed and will not review the registration statement. The SEC's letter also reminds the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The letter further refers Biodexa Pharmaceuticals to Rules 460 and 461 should they wish to request acceleration of the process. Chris Edwards from the SEC's Division of Corporation Finance Office of Life Sciences has been designated as the contact person for any questions Biodexa Pharmaceuticals might have.